CUE BIOPHARMA INC (CUE:NASDAQ)
$18.67 0.07 (0.3763%)
Analysed CUE BIOPHARMA INC (CUE:NASDAQ) News Sources
Cue Biopharma Announces $30 Million Private Placement
30-04-2026
yahoo.com
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
30-04-2026
yahoo.com
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments
14-05-2026
yahoo.com
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference
21-05-2026
yahoo.com
Cue Biopharma Announces $50.0 Million Private Placement
10-07-2026
yahoo.com
Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
20-09-2026
yahoo.com
Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
21-09-2026
advfn.com
An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
22-09-2026
biopharmadive.com
Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
26-09-2026
yahoo.com
Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
28-09-2026
marketbeat.com
What is the current price of CUE BIOPHARMA INC (CUE:NASDAQ)?
The current price of CUE BIOPHARMA INC (CUE:NASDAQ) is $18.67.
CUE BIOPHARMA INC (CUE:NASDAQ) absolute price change since previous trading day?
The absolute price change of CUE BIOPHARMA INC (CUE:NASDAQ) since the previous trading day is $0.07.
CUE BIOPHARMA INC (CUE:NASDAQ) percentage price change since previous trading day?
The percentage price change of CUE BIOPHARMA INC (CUE:NASDAQ) since the previous trading day is 0.3763%.
What is the most recent average sentiment score for CUE BIOPHARMA INC (CUE:NASDAQ)?
The most recent average sentiment score for CUE BIOPHARMA INC (CUE:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for CUE BIOPHARMA INC (CUE:NASDAQ)?
The most recent sentiment for CUE BIOPHARMA INC (CUE:NASDAQ) is .
SEC-8K** Filing Available For CUE BIOPHARMA INC (CUE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.